Front-Line Treatment with Second-Generation Tyrosine Kinase Inhibitors Following By Allo-Transplantation Benefits Patients with Better Survival Inph-Positive Acute Lymphoblastic Leukemia

被引：0
|
作者：
Yu, Pan
Chen, Fang
Xu, Dan
Yin, Changxin
Liu, Qifa
Sun, Jing
Fan, Zhiping
Wang, Qiang
Liu Xiaoli
Jiang, Qianli
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4522
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Upfront treatment with the first and second-generation tyrosine kinase inhibitors in Ph-positive acute lymphoblastic leukemia
    Yu, Guopan
    Chen, Fang
    Yin, Changxin
    Liu, Qifa
    Sun, Jing
    Xuan, Li
    Fan, Zhiping
    Wang, Qiang
    Liu, Xiaoli
    Jiang, Qianli
    Xu, Dan
    ONCOTARGET, 2017, 8 (63): : 107022 - 107032
  • [2] Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia
    Jabbour, Elias
    DerSarkissian, Maral
    Duh, Mei Sheng
    McCormick, Nora
    Cheng, Wendy Y.
    McGarry, Lisa J.
    Souroutzidis, Ariadne
    Huang, Hui
    O'Brien, Susan
    Ravandi, Farhad
    Kantarjian, Hagop M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (04): : 257 - 265
  • [3] Comparison of the Efficacy of the First and Second-Generation Tyrosine Kinase Inhibitors in the First-Line Treatment of Ph-Positive Acute Lymphoblastic Leukemia
    Yu, Guopan
    Xu, Dan
    Liu, Qifa
    Sun, Jing
    Fan, Zhiping
    Wang, Qiang
    Liu, Xiaoli
    Jiang, Qianli
    BLOOD, 2015, 126 (23)
  • [4] Impact of Second-Generation Tyrosine Kinase Inhibitors As Second Line Treatment for Patients with Chronic Myeloid Leukemia
    Valentin Garcia-Gutierrez, J.
    Herrera, Pilar
    Abalo, Lorena L.
    Dolores Rey, Maria
    Calbacho, Maria
    Ramos, Lourdes
    Ramos, Paloma
    Montalban, Carlos
    Lopez-Jimenez, Javier
    BLOOD, 2011, 118 (21) : 1615 - 1615
  • [5] Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?
    Jabbour, Elias
    Kantarjian, Hagop M.
    O'Brien, Susan
    Shan, Jianqin
    Quintas-Cardama, Alfonso
    Garcia-Manero, Guillermo
    Rios, Mary Beth
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4260 - 4265
  • [6] Second-Generation Tyrosine Kinase Inhibitors in the Post-Transplant Period in Patients with Chronic Myeloid Leukemia or Philadelphia-Positive Acute Lymphoblastic Leukemia
    Klyuchnikov, Evgeny
    Schafhausen, Philippe
    Kroeger, Nicolaus
    Brummendorf, Tim H.
    Osanmaz, Okay
    Asenova, Svetlana
    Zabelina, Tatjana
    Ocheni, Sunday
    Ayuk, Francis
    Zander, Axel R.
    Bacher, Ulrike
    ACTA HAEMATOLOGICA, 2009, 122 (01) : 6 - 10
  • [7] THE FIRST AND SECOND GENERATION TYROSINE KINASE INHIBITORS ROLE IN THE PHILADELPHIA POSITIVE CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
    Koc, Basak
    Zulfikar, Bulent
    PEDIATRIC BLOOD & CANCER, 2015, 62 : 84 - 84
  • [8] Comparison of clinical efficacy between first-generation and second-generation tyrosine kinase inhibitors based regimen in the treatment of patients with BCR-ABL positive acute lymphoblastic leukemia
    刘莹
    China Medical Abstracts (Internal Medicine), 2019, 36 (04) : 230 - 230
  • [9] SECOND-GENERATION TYROSINE KINASE INHIBITORS AS SECOND LINE TREATMENT IMPROVE OUTCOME OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA RESISTANT OR INTOLERANT TO IMATINIB
    Casado Montero, L. F.
    Garcia-Gutierrez, V.
    Maestro, B.
    Massague, I.
    Giraldo, P.
    Perez-Encinas, M.
    De Paz, R.
    Martinez-Lopez, J.
    Bautista, G.
    Osorio, S.
    Requena, M. J.
    Palomera, L.
    Penarrubia, M. J.
    Dumas, M. H.
    Garcia-Ormena, N.
    Calle, C.
    Hernandez-Rivas, J. A.
    Steegmann, J. L.
    HAEMATOLOGICA, 2012, 97 : 535 - 535
  • [10] Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors
    Garcia-Gutierrez, Valentin
    Hernandez-Boluda, Juan Carlos
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (07) : 1 - 14
12345